US Financial Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

US Financial Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-245	Closed	-$11K	–	640
2015 Q4	$11K	Hold	245	–	–	0.01%	312
2015 Q3	$10K	Hold	245	–	–	0.02%	263
2015 Q2	$13K	Hold	245	–	–	0.01%	219
2015 Q1	$15K	Buy	+245	New	+$11.9K	0.01%	227

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

US Financial Advisors's JUNO Position: Q1 2016 in Review

US Financial Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 245 shares — an estimated $11K sold.

US Financial Advisors first reported a position in JUNO in Q1 2015 and held it in 4 quarters. The position peaked at $15K in Q1 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

US Financial Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
US Financial Advisors sold 245 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $11K.
US Financial Advisors first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 4 quarters.
US Financial Advisors's Juno Therapeutics, Inc. position peaked at $15K in Q1 2015.
158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on US Financial Advisors's 13F filing for Q1 2016, filed 5 May 2016.